Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L2 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

PD-L2 overexpression	Prostate Cancer	PD-L2 overexpression	Prostate Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-L2 overexpression	Melanoma	PD-L2 overexpression	Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-L2 overexpression	Melanoma	PD-L2 overexpression	Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
PD-L2 overexpression	Melanoma	PD-L2 overexpression	Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck	PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L2 overexpression	Triple Negative Breast Cancer	PD-L2 overexpression	Triple Negative Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L2 overexpression	Triple Negative Breast Cancer	PD-L2 overexpression	Triple Negative Breast Cancer	capecitabine Sensitive: C3 – Early Trials capecitabine Sensitive : C3	capecitabine Sensitive: C3 – Early Trials capecitabine Sensitive : C3
PD-L2 overexpression	Acute Myelogenous Leukemia	PD-L2 overexpression	Acute Myelogenous Leukemia	avelumab Resistant: D – Preclinical avelumab Resistant : D	avelumab Resistant: D – Preclinical avelumab Resistant : D
PD-L2 overexpression	Colorectal Adenocarcinoma	PD-L2 overexpression	Colorectal Adenocarcinoma	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + PD-L2 inhibitor Sensitive : D	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + PD-L2 inhibitor Sensitive : D
PD-L2 overexpression	Endometrial Cancer	PD-L2 overexpression	Endometrial Cancer	paclitaxel Sensitive: D – Preclinical paclitaxel Sensitive : D	paclitaxel Sensitive: D – Preclinical paclitaxel Sensitive : D